Eymard Jean-Christophe, Gervais Alban, Jarcau Rosana, Bernard Jacky
Unité fonctionnelle de recherche clinique et de thérapie cellulaire.
Bull Cancer. 2007 Jul;94(7 Suppl):F69-76.
Therapeutic vaccines for prostate cancer were initially reported as limited with low immunological responses and uncertain clinical benefit. Recently, new methods become available, such preparations of well-characterized autologous dendritic cells, and use of gene therapy tools to increase whole-tumor cells or host tissue immunogenicity. These are able to enhance and diversify therapeutic options. Indeed, several vaccinal approaches are being investigated, including optimized mature dendritic cells, allogeneic genetically modified tumor cells, or viral vectors. Due to the description of immunological and clinical responses, large phase III randomized trials are now conducted. After summarizing the mechanistic basis for these approaches, this review describes the experience with the most recent and promising clinical studies and introduces short-term perspectives that could lead to improvement in healthcare offer for prostate cancer patients.
前列腺癌治疗性疫苗最初被报道效果有限，免疫反应低且临床益处不确定。最近，出现了新的方法，比如制备特征明确的自体树突状细胞，以及使用基因治疗工具来提高全肿瘤细胞或宿主组织的免疫原性。这些方法能够增加并丰富治疗选择。确实，目前正在研究几种疫苗接种方法，包括优化的成熟树突状细胞、同种异体基因改造肿瘤细胞或病毒载体。鉴于对免疫和临床反应的描述，现在正在进行大型III期随机试验。在总结这些方法的机制基础后，本综述描述了最新且有前景的临床研究经验，并介绍了可能会改善前列腺癌患者医疗服务的短期前景。
